AS
SRPT icon

AM Squared’s Sarepta Therapeutics SRPT Stock Holding History

AM Squared’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$175K Buy
1,400
+1,200
+600% +$166K 0.39% 20
2024
Q2 		$31.6K Sell
200
-400
-67% -$51.4K 0.08% 64
2024
Q1 		$77.7K Buy
+600
New +$73.5K 0.19% 20

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AM Squared's SRPT Position: Q3 2024 in Review

AM Squared increased its Sarepta Therapeutics (SRPT) stake by 600% in Q3 2024, buying an estimated $166K and bringing the position to 1,400 shares worth $175K. The position accounts for 0.39% of the portfolio, ranked #20.

AM Squared first reported a position in SRPT in Q1 2024 and has held it in 3 quarters since. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • AM Squared held 1,400 shares of Sarepta Therapeutics worth $175K as of Q3 2024.
  • AM Squared bought 1,200 Sarepta Therapeutics shares in Q3 2024, an estimated $166K.
  • Sarepta Therapeutics made up 0.39% of AM Squared's portfolio in Q3 2024, its #20 holding.
  • AM Squared first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.